Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors
Journal of Clinical Medicine · 31.12.2024 · 14 (1) · 188
DOI: 10.3390/jcm14010188 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 31.12.2024. Verfasst von Alexandra Laura Mederle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Victor Babes” University of Medicine and Pharmacy Timisoara, Romania.
Abstract (Originalsprache)
Diabetes is a complex global healthcare burden involving multiple organ systems with its prevalence on the rise. SGLT2 inhibitors enhance glucose excretion. The objective of our literature review was to determine the association between cutaneous adverse drug reactions (CADRs) and the use of SGLT2 inhibitors. We collected data on CADRs related to the use of SGLT2 inhibitors from all available published articles and studied their details to understand the patterns of their association. PubMed, Cochrane, Google, and Embase were searched for relevant articles. A total of 37 papers were included and studied. Most articles were case reports followed by pharmacovigilance studies, case series, and reviews. The cutaneous findings ranged from benign eruptions to severe reactions. The available literature suggests a strong link between the use of SGLT2 inhibitors and Fournier’s gangrene/necrotizing fasciitis. T2DM patients using SGLT2 inhibitors have also developed fixed drug eruptions, drug-induced pruritus, and Sweet syndrome/acute febrile neutrophilic dermatosis, among other skin lesions. We found that SGLT2 inhibitors present a risk of developing CADRs. Raising awareness among healthcare providers regarding CADRs to SGLT2 inhibitors can reduce complications, minimize hospitalizations, and improve patient care in the vulnerable population of diabetes patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Discipline of Pathophysiology, Department of Functional Science, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Center for Translational Research and Systems Medicine, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Centre of Cognitive Research in Pathological Neuro-Psychiatry NEUROPSY-COG, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Department of Cardiology-Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Research Centre of Timișoara Institute of Cardiovascular Diseases, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
ORCID-Profile: Nilima Rajpal Kundnani
Förderung
- “Victor Babes” University of Medicine and Pharmacy Timisoara, Romania
Zitieren
APA
Mederle, A. L., Dumitrescu, P., Borza, C., & Kundnani, N. R. (2024). Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors. Journal of Clinical Medicine, 14(1), 188. https://doi.org/10.3390/jcm14010188
Vancouver
Mederle AL, Dumitrescu P, Borza C, Kundnani NR. Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors. Journal of Clinical Medicine. 2024;14(1):188. doi:10.3390/jcm14010188
BibTeX
@article{Mederle2024,
author = {Mederle, Alexandra Laura and Dumitrescu, Patrick and Borza, Claudia and Kundnani, Nilima Rajpal},
title = {Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {14},
number = {1},
pages = {188},
doi = {10.3390/jcm14010188}
}
EUVIMED